ETC
Exchange Traded Concepts Portfolio holdings
AUM
$7.83B
1-Year Return
24.45%
This Quarter Return
-3.99%
1 Year Return
+24.45%
3 Year Return
+83.69%
5 Year Return
+131.49%
10 Year Return
–
AUM
$3.53B
AUM Growth
-$528M
(-13%)
Cap. Flow
-$328M
Cap. Flow
% of AUM
-9.28%
Top 10 Holdings %
Top 10 Hldgs %
29.69%
Holding
1,565
New
259
Increased
499
Reduced
543
Closed
256
Top Buys
| 1 |
Goldman Sachs Access Treasury 0-1 Year ETF
GBIL
|
+$366M |
| 2 |
iShares 0-3 Month Treasury Bond ETF
SGOV
|
+$365M |
| 3 |
Emerson Electric
EMR
|
+$26.1M |
| 4 |
Vanguard Energy ETF
VDE
|
+$24.2M |
| 5 |
UnitedHealth
UNH
|
+$16.1M |
Top Sells
| 1 |
Vanguard Long-Term Bond ETF
BLV
|
+$158M |
| 2 |
iShares Core US REIT ETF
USRT
|
+$141M |
| 3 |
Technology Select Sector SPDR Fund
XLK
|
+$138M |
| 4 |
Vanguard Extended Market ETF
VXF
|
+$101M |
| 5 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$69.4M |
Sector Composition
| 1 | Technology | 21.26% |
| 2 | Energy | 11.87% |
| 3 | Healthcare | 10.76% |
| 4 | Industrials | 6.89% |
| 5 | Consumer Discretionary | 5.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
DCPH
901
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $99.2K | ﹤0.01% |
7,798
-2,005
| -20% | -$25.5K |
|
902
ImmunityBio
IBRX
$2.28B
| $98.3K | ﹤0.01% |
58,136
+10,596
| +22% | +$17.9K |
|
903
Tyra Biosciences
TYRA
$646M
| $98K | ﹤0.01% |
7,114
-1,753
| -20% | -$24.1K |
|
904
Zymeworks
ZYME
$1.15B
| $97.6K | ﹤0.01% |
15,389
-1,139
| -7% | -$7.22K |
|
|
THRX
905
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $97.4K | ﹤0.01% |
36,210
+21,419
| +145% | +$57.6K |
|
906
Genmab
GMAB
$16.9B
| $97.2K | ﹤0.01% |
2,755
-941
| -25% | -$33.2K |
|
907
Compass Therapeutics
CMPX
$590M
| $96.8K | ﹤0.01% |
49,129
+5,924
| +14% | +$11.7K |
|
908
IDEAYA Biosciences
IDYA
$2.05B
| $96.8K | ﹤0.01% |
3,587
-2,063
| -37% | -$55.7K |
|
909
Kura Oncology
KURA
$707M
| $96.5K | ﹤0.01% |
10,581
-594
| -5% | -$5.42K |
|
|
SWAV
910
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $96.2K | ﹤0.01% |
483
+50
| +12% | +$9.96K |
|
911
Madrigal Pharmaceuticals
MDGL
$10.1B
| $95.7K | ﹤0.01% |
655
+487
| +290% | +$71.1K |
|
912
Vor Biopharma
VOR
$251M
| $95.2K | ﹤0.01% |
44,912
+17,365
| +63% | +$36.8K |
|
913
Pricesmart
PSMT
$3.44B
| $95.1K | ﹤0.01% |
1,278
+616
| +93% | +$45.8K |
|
914
Cullinan Oncology
CGEM
$404M
| $95.1K | ﹤0.01% |
10,507
-1,154
| -10% | -$10.4K |
|
915
Biomea Fusion
BMEA
$108M
| $95K | ﹤0.01% |
6,903
+3,329
| +93% | +$45.8K |
|
916
Acrivon Therapeutics
ACRV
$56.3M
| $94.8K | ﹤0.01% |
9,919
-1,790
| -15% | -$17.1K |
|
|
PNT
917
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $94.4K | ﹤0.01% |
14,160
+58
| +0.4% | +$387 |
|
918
Relay Therapeutics
RLAY
$700M
| $93.9K | ﹤0.01% |
11,168
-899
| -7% | -$7.56K |
|
919
Mersana Therapeutics
MRSN
$35.1M
| $93.6K | ﹤0.01% |
2,948
+2,336
| +382% | +$74.2K |
|
920
Oceaneering
OII
$2.41B
| $93.5K | ﹤0.01% |
+3,634
| New | +$93.5K |
|
921
Recursion Pharmaceuticals
RXRX
$2.02B
| $93.4K | ﹤0.01% |
12,211
-2,089
| -15% | -$16K |
|
922
Domino's
DPZ
$15.8B
| $93.2K | ﹤0.01% |
246
+182
| +284% | +$68.9K |
|
|
ITOS
923
DELISTED
iTeos Therapeutics
ITOS
| $93K | ﹤0.01% |
8,494
-1,130
| -12% | -$12.4K |
|
924
Sutro Biopharma
STRO
$83.3M
| $92.9K | ﹤0.01% |
26,764
+1,153
| +5% | +$4K |
|
925
Nurix Therapeutics
NRIX
$742M
| $92.8K | ﹤0.01% |
11,811
-528
| -4% | -$4.15K |
|